Sort by
Refine Your Search
-
Listed
-
Field
-
Fellowship within the laboratory of Dr Ed Boas, at the Beckman Research Institute of City of Hope. For more information on his research please visit here . We are looking for a biomedical engineer, materials
-
involved in cutting-edge technology, research and clinical immunotherapy investigations. We are currently looking for a postdoctoral fellow who will work on improving the therapeutic potential of oncolytic
-
labs involved in cutting edge technology, research, and clinical immunotherapeutic programs. Dr. Lior Goldberg’s lab currently has an opening for a Postdoctoral Fellow who will develop chimeric antigen
-
on projects investigating the new pathways and targets in diabetes/obesity and other metabolic diseases. We use genetically engineered mouse models and molecular pharmacology tools to identify novel signaling
-
transduction, ELISA, CART production, CRISPR/Cas9 technology · In vivo skills: o Routes of drug administration: oral gavage, intraperitoneal, retro-orbital, subcutaneous, or tail vein injections o
-
malignancies using engineered cellular therapies. We are looking for a highly motivated candidate with a PhD and/or MD degree interested in combining novel rational and combinatorial synthetic biology approaches
-
well as disease relapse in order to design novel inhibitors to intervene the malignancies; 3) collaborative analyses of myeloid cancers genomics using high-throughput single-cell technology. The group conducts
-
labs involved in cutting edge technology, research, and clinical immunotherapeutic programs. Dr. Lior Goldberg’s lab currently has an opening for a Postdoctoral Fellow who will develop chimeric antigen
-
leukemogenesis as well as disease relapse in order to design novel inhibitors to intervene the malignancies · Collaborative analyses of myeloid cancers genomics using high-throughput single-cell technology
-
are seeking a fast-paced academic research environment. Our lab in the Department of Immuno-Oncology focuses on engineering tumor-colonizing bacteria to target components of the tumor microenvironment